Investing.com - H.C. Wainwright has reiterated its Buy rating and $12.00 price target on Microbot Medical (NASDAQ:MBOT), following the company’s first hospital adoption announcement. The stock ...
Fintel reports that on November 28, 2025, HC Wainwright & Co. reiterated coverage of Microbot Medical (NasdaqCM:MBOT) with a Buy recommendation. Analyst Price Forecast Suggests 434.50% Upside As of ...
HINGHAM, Mass., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY Endovascular Robotic System, announced that Emory University ...
KUALA LUMPUR: Over 100,000 technologists and technicians including those specialising in emerging technologies are currently registered under the Malaysia Board of Technologists (MBOT), says Chang Lih ...
Hosted on MSN
Microbot Medical Launches LIBERTY® System in U.S.
Microbot Medical ( (MBOT)) has issued an announcement. On November 5, 2025, Microbot Medical announced the limited commercial availability of its LIBERTY® Endovascular Robotic System in the U.S. This ...
Harel Gadot, CEO of Microbot Medical Inc. (NASDAQ:MBOT), was recently a guest on Benzinga's All Access. Microbot Medical makes the LIBERTY® Endovascular Robotic System, a single-use, fully disposable ...
We recently published 10 Stocks Losing Big Amid Market Boom. Microbot Medical Inc. (NASDAQ:MBOT) is one of the worst performers on Thursday. Microbot extended its losing streak to a fourth consecutive ...
MBOT’s main value driver is its LIBERTY robot. This is a disposable, portable endovascular robot that has great potential. LIBERTY showed strong ACCESS-PVI data and now awaits FDA 510(k) clearance for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results